These findings underscore the multifaceted roles of non-coding RNAs in prostate cancer and highlight the potential of targeting specific SNHG-sdRNA axes for therapeutic intervention, such as disrupting the SNHG4/SP1 or SNHG11/IGF-1R pathways. Here, SP1 is linked to prostate carcinoma.